Citadel Advisors’s Sutro Biopharma STRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.39M | Sell |
101,965
-15,572
| -13% | -$486K | ﹤0.01% | 5450 |
|
|
2026
Q1 | $2.93M | Buy |
117,537
+85,452
| +266% | +$1.54M | ﹤0.01% | 5313 |
|
|
2025
Q4 | $371K | Buy |
+32,085
| New | +$304K | ﹤0.01% | 9694 |
|
|
2025
Q2 | – | Sell |
-14,123
| Closed | -$115K | – | 14983 |
|
|
2025
Q1 | $91.9K | Sell |
14,123
-231,743
| -94% | -$3.65M | ﹤0.01% | 11594 |
|
|
2024
Q4 | $4.52M | Buy |
245,866
+33,200
| +16% | +$1.01M | ﹤0.01% | 4119 |
|
|
2024
Q3 | $7.36M | Buy |
212,666
+50,675
| +31% | +$1.99M | ﹤0.01% | 3360 |
|
|
2024
Q2 | $4.75M | Buy |
161,991
+127,917
| +375% | +$5.06M | ﹤0.01% | 3829 |
|
|
2024
Q1 | $1.93M | Buy |
34,074
+20,881
| +158% | +$922K | ﹤0.01% | 5603 |
|
|
2023
Q4 | $566K | Buy |
13,193
+8,334
| +172% | +$264K | ﹤0.01% | 7823 |
|
|
2023
Q3 | $169K | Buy |
4,859
+2,026
| +72% | +$88.3K | ﹤0.01% | 10175 |
|
|
2023
Q2 | $132K | Sell |
2,833
-30,084
| -91% | -$1.5M | ﹤0.01% | 10521 |
|
|
2023
Q1 | $1.52M | Buy |
32,917
+20,917
| +174% | +$1.33M | ﹤0.01% | 5885 |
|
|
2022
Q4 | $970K | Sell |
12,000
-18,209
| -60% | -$1.27M | ﹤0.01% | 6877 |
|
|
2022
Q3 | $1.68M | Sell |
30,209
-31,361
| -51% | -$1.86M | ﹤0.01% | 5930 |
|
|
2022
Q2 | $3.21M | Buy |
61,570
+25,785
| +72% | +$1.44M | ﹤0.01% | 4637 |
|
|
2022
Q1 | $2.94M | Sell |
35,785
-23,892
| -40% | -$2.27M | ﹤0.01% | 5236 |
|
|
2021
Q4 | $8.88M | Sell |
59,677
-7,287
| -11% | -$1.31M | ﹤0.01% | 3272 |
|
|
2021
Q3 | $12.6M | Sell |
66,964
-9,035
| -12% | -$1.72M | ﹤0.01% | 2669 |
|
|
2021
Q2 | $14.1M | Sell |
75,999
-21,663
| -22% | -$4.24M | ﹤0.01% | 2561 |
|
|
2021
Q1 | $22.2M | Sell |
97,662
-31,638
| -24% | -$7.51M | 0.01% | 1828 |
|
|
2020
Q4 | $28.1M | Buy |
129,300
+7,287
| +6% | +$1.21M | 0.01% | 1451 |
|
|
2020
Q3 | $12.3M | Sell |
122,013
-5,139
| -4% | -$486K | ﹤0.01% | 2051 |
|
|
2020
Q2 | $9.9M | Sell |
127,152
-27,783
| -18% | -$2.67M | ﹤0.01% | 2229 |
|
|
2020
Q1 | $15.8M | Sell |
154,935
-17,963
| -10% | -$1.89M | 0.01% | 1430 |
|
|
2019
Q4 | $19M | Sell |
172,898
-82
| -0% | -$8.45K | 0.01% | 1530 |
|
|
2019
Q3 | $15.7M | Buy |
172,980
+145
| +0.1% | +$14.6K | 0.01% | 1711 |
|
|
2019
Q2 | $19.7M | Sell |
172,835
-85
| -0% | -$9.37K | 0.01% | 1445 |
|
|
2019
Q1 | $19.7M | Buy |
172,920
+16
| +0% | +$1.66K | 0.01% | 1351 |
|
|
2018
Q4 | $15.6M | Sell |
172,904
-1,938
| -1% | -$234K | 0.01% | 1432 |
|
|
2018
Q3 | $26.2M | Buy |
+174,842
| New | +$26.4M | 0.01% | 1180 |
|
Other funds holding STRO
KCM
Citadel Advisors's STRO Position: Q2 2026 in Review
Citadel Advisors reduced its Sutro Biopharma (STRO) stake by 13% in Q2 2026, selling an estimated $486K and leaving 101,965 shares worth $3.39M. The position accounts for ﹤0.01% of the portfolio, ranked #5450.
Citadel Advisors first reported a position in STRO in Q3 2018 and has held it in 30 quarters since. The position peaked at $28.1M in Q4 2020. 100 funds tracked by Wall St. Rank hold STRO as of Q2 2026.
- Citadel Advisors held 101,965 shares of Sutro Biopharma worth $3.39M as of Q2 2026.
- Citadel Advisors sold 15,572 Sutro Biopharma shares in Q2 2026, an estimated $486K.
- Sutro Biopharma made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #5450 holding.
- Citadel Advisors first reported a position in Sutro Biopharma in Q3 2018 and has held it in 30 quarters since.
- Citadel Advisors's Sutro Biopharma position peaked at $28.1M in Q4 2020.
- 100 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2026.
Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.